Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Feng Zhang

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
BMC Medical Genetics|October 23, 2019
MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancerLi-Feng Zhang, Li-Jie Zhu, Wei Zhang, et al.
Oncotarget|November 2, 2017
Association of a common genetic variant in RNASEL and prostate cancer susceptibilityLi Zuo, Ke-Wei Ren, Yu Bai, et al.
Aging|August 1, 2018
Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancerHong-Bao Shao, Kewei Ren, Sheng-Lin Gao, et al.
World Journal of Gastroenterology|February 26, 2011
Influence of CXCR4/SDF-1 axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cellsLin Wang, Cui-Ling Li, Lei Wang, et al.
Aging|January 14, 2020
Association between SOD2 V16A variant and urological cancer riskLi-Feng Zhang, Kai Xu, Bo-Wen Tang, et al.
Medical Oncology (Northwood, London, England)|May 22, 2010
Review and pooled analysis of studies on -607(C/A) and -137(G/C) polymorphisms in IL-18 and cancer riskYuan-Yuan Mi, Qian-Qian Yu, Meng-Lei Yu, et al.
Journal of Leukocyte Biology|September 26, 2022
ILC3-like ILC2 subset increases in minimal persistent inflammation after acute type II inflammation of allergic rhinitis and inhibited by Biminkang: Plasticity of ILC2 in minimal persistent inflammationXiang-Jing Chen, Cheng Liu, Shan Zhang, et al.
Molecular Biology Reports|June 21, 2012
Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysisYa-Ling Liang, Hua Wu, Xi Shen, et al.
Bioscience Reports|November 11, 2018
Association between three genetic variants in kallikrein 3 and prostate cancer riskWei-Hong Ding, Ke-Wei Ren, Chuang Yue, et al.
Drug Discovery Today|November 12, 2022
Breaking boundaries: Current progress of anticancer NK cell-based drug developmentShuhang Wang, Kun Chen, Yale Jiang, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
BMC Medical Genetics|October 23, 2019
MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancerLi-Feng Zhang, Li-Jie Zhu, Wei Zhang, et al.
Oncotarget|November 2, 2017
Association of a common genetic variant in RNASEL and prostate cancer susceptibilityLi Zuo, Ke-Wei Ren, Yu Bai, et al.
Aging|August 1, 2018
Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancerHong-Bao Shao, Kewei Ren, Sheng-Lin Gao, et al.
World Journal of Gastroenterology|February 26, 2011
Influence of CXCR4/SDF-1 axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cellsLin Wang, Cui-Ling Li, Lei Wang, et al.
Aging|January 14, 2020
Association between SOD2 V16A variant and urological cancer riskLi-Feng Zhang, Kai Xu, Bo-Wen Tang, et al.
Medical Oncology (Northwood, London, England)|May 22, 2010
Review and pooled analysis of studies on -607(C/A) and -137(G/C) polymorphisms in IL-18 and cancer riskYuan-Yuan Mi, Qian-Qian Yu, Meng-Lei Yu, et al.
Journal of Leukocyte Biology|September 26, 2022
ILC3-like ILC2 subset increases in minimal persistent inflammation after acute type II inflammation of allergic rhinitis and inhibited by Biminkang: Plasticity of ILC2 in minimal persistent inflammationXiang-Jing Chen, Cheng Liu, Shan Zhang, et al.
Molecular Biology Reports|June 21, 2012
Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysisYa-Ling Liang, Hua Wu, Xi Shen, et al.
Bioscience Reports|November 11, 2018
Association between three genetic variants in kallikrein 3 and prostate cancer riskWei-Hong Ding, Ke-Wei Ren, Chuang Yue, et al.
Drug Discovery Today|November 12, 2022
Breaking boundaries: Current progress of anticancer NK cell-based drug developmentShuhang Wang, Kun Chen, Yale Jiang, et al.
Pageof 14